Testimony to FDA on Flibanserin

Endocrine Society Testimony to the Joint Meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee

"The Society is encouraged by the FDA’s focus on drug development for FSD, but cautions that most existing medications should be limited in their use due to limited efficacy data from studies published to date. However, studies with flibanserin show an effect size similar or greater than studies for drugs for male sexual dysfunction. Thus, similar levels of evidence should be used to approve drugs for women as for men. "

Read the Full Testimony

Policy Communications